Arcus Biosciences (NYSE:RCUS) appointed Eric Hoefer as its chief commercial officer to oversee the company’s global commercial strategy and operations.
Arcus is focused on developing innovative cancer immunotherapies, with both small molecule and monoclonal antibody candidates in its development pipeline.
“Eric has extensive knowledge of the global clinical and commercial oncology treatment landscape,” Terry Rosen, Arcus’ CEO, said in a statement.
“His insights into identifying underserved patient populations and settings, market development opportunities and potential approaches to accelerate development programs will be invaluable as the company evolves towards later-stage clinical studies,” he added.
During Mr. Hoefer’s 20 years of experience in bio-pharmaceuticals, he has played key roles in the development and commercialization of 15 new medicines, including several cancer immunotherapies. Most recently, Mr. Hoefer led AstraZeneca’s immuno-oncology (IO) global marketing group, which launched the first IO medicine approved in the curative-intent lung cancer setting. Mr. Hoefer launched seven new medicines and led the commercial development of late-stage oncology candidates during his 14-year tenure with Roche/Genentech, as well as co-led the development of a Phase 1b/2 platform to advance novel IO combination approvals across seven tumor types.
